Geistlich News

13. November 2019

Significant recognition for Geistlich in China

Success for Geistlich at the Sino-Swiss Business Awards held every two years. In the category of the “Nestlé award for outstanding achievements of an SME”, the family company from Central Switzerland won the top award and considerable recognition for the successful development of its business in China.

The gala evening for the presentation of the Sino-Swiss Business Awards was an occasion that both Switzerland’s ambassador to China, Bernardino Regazzoni, and Zhai Qian from the Chinese Ministry of Commerce were keen to attend.    

Geistlich driving Chinese dentistry ahead

It was a bold decision and one made early on: Geistlich, the pioneer and innovator of biomaterials, set up its affiliate in China back in 2008, and its considerable experience and expertise attracted significant interest. Geistlich continues to have a strong influence on Chinese implantology to this day. The award is recognition for its consistent and long-term development. Geistlich CEO Paul Note was delighted: “Our performance with Chinese patients is reflected in our consistent success eleven years after entering the market.” In the meantime the huge demand from Chinese patients and their satisfaction with the company has made China the company’s largest market.

Providing motivation and an incentive to do more

In all, more than 80 Swiss and Chinese companies entered for awards in eight categories. The event is organized by the Swiss Chamber of Commerce (SwissCham) in China and other partners. The companies considered for awards are those that are making a crucial contribution to Chinese-Swiss economic collaboration and the promotion of Switzerland in China. The awards were judged by an independent ten-person jury. General Manager Wang Qiu and Chief Commercial Officer Marco Bollier accepted the coveted award on behalf of the team of around 50 employees of Geistlich Pharma in China. Wang Qiu said: “This award provides us with the incentive and motivation to continue serving Chinese patients.”